Document Detail


Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment.
MedLine Citation:
PMID:  19663597     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Treatment of visceral leishmaniasis (VL) is far from satisfactory. There is an urgent need for a therapy that is efficacious, safe, affordable, and of short duration. METHODS: A randomized open-label study was conducted to assess the efficacy and safety of 2 regimens of paromomycin administered intramuscularly. Group A received 11 mg/kg/day for 14 days (n = 217) and group B received 11 mg/kg/day for 21 days (n = 112) for the treatment of VL in India. RESULTS: Mild grade injection site pain was the most common adverse event. There was no nephrotoxicity, but 4 patients in group A had to discontinue treatment because of grade 3 elevation of hepatic enzymes. Initial cure was observed in 91.2% and 96.4% of patients in group A and group B, respectively. Definitive cure at 6 months of follow up was seen in 82% of patients in group A and 92% of patients in group B by intention-to-treat analysis and in 84.3% of patients in group A and 92.8% of patients in group B by per protocol analysis. CONCLUSIONS: Although the cure rate in the group of patients who received the 14-day regimen was not optimal, the results with respect to initial cure were encouraging. Further studies that combine a short course of paromomycin with treatment with another antileishmanial agent are warranted. ( ClinicalTrials.gov identifier: NCT00629031).
Authors:
Shyam Sundar; Neha Agrawal; Rakesh Arora; Dipti Agarwal; Madhukar Rai; Jaya Chakravarty
Related Documents :
9352407 - A retrospective study of the clinical presentation and outcome of herpes zoster in a te...
2942457 - Topical treatment of recurrent genital herpes simplex virus infections with trisodium p...
17670157 - Management of postpneumonectomy aspergillus empyema extending into the thoracic wall: a...
3027837 - Itraconazole in pityriasis versicolor.
3107487 - Maintenance etidronate in the prevention of malignancy-associated hypercalcemia.
18077177 - Pulmonary endarterectomy is possible and effective without the use of complete circulat...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America     Volume:  49     ISSN:  1537-6591     ISO Abbreviation:  Clin. Infect. Dis.     Publication Date:  2009 Sep 
Date Detail:
Created Date:  2009-08-21     Completed Date:  2009-11-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9203213     Medline TA:  Clin Infect Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  914-8     Citation Subset:  IM    
Affiliation:
Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India. drshyamsundar@hotmail.com
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT00629031
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Animals
Antiprotozoal Agents / administration & dosage,  adverse effects,  therapeutic use*
Child
Child, Preschool
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Humans
India
Injections, Intramuscular / adverse effects
Leishmaniasis, Visceral / drug therapy*
Male
Middle Aged
Paromomycin / administration & dosage,  adverse effects,  therapeutic use*
Time Factors
Treatment Outcome
Young Adult
Chemical
Reg. No./Substance:
0/Antiprotozoal Agents; 7542-37-2/Paromomycin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The status of in vitro toxicity studies in the risk assessment of nanomaterials.
Next Document:  Dried blood spots perform well in viral load monitoring of patients who receive antiretroviral treat...